Colley Shroyer Abraham are reviewing claims against Johnson & Johnson (Ethicon Division) concerning their Morcellator surgical tool, a tool most commonly used in laparoscopic procedures, specifically hysterectomies and myomectomies (surgery to remove uterine fibroids). Johnson & Johnson withdrew from the global market, on July 30th 2014, three different Ethicon power morcellators after studies found the devices may scatter undetected cancer cells around a woman’s body. The products involved are: (1) Gynecare Morcellex Tissue Morcellator; (2) Morcellex Sigma Tissue Morcellator System; and (3) Gynecare X-Tract Tissue Morcellator.
Cancers most commonly associated with the use of a laparoscopic morcellator include: abdominal, pelvic and uterine sarcoma (leiomyosarcoma or endometrial stromal sarcoma (ESS). Other injuries include benign tissue which can lead to pain, infection or bowel obstruction or injuries to other organs.
Johnson & Johnson suspended sales and distribution of these surgical tools after the FDA issued a warning on April 17, 2014 that these devices, when used in patients with unsuspected or undiagnosed uterine cancer, may cause the spread of cancerous tissue through the abdomen and pelvis.
These products have been on the market since early 2000 and approximately 60,000 women undergo one of these procedures annually.
We are interested in reviewing any case where any of the following is present: (1) a Johnson & Johnson morcellator surgical tool has been used in either a hysterectomy or myomectomy procedure; and (2) the client has been diagnosed with abdominal, pelvic or uterine sarcoma.
Our highly skilled medical staff at Colley Shroyer Abraham are investigating Ethicon Morcellator claims. Our professionals are available now to help you.
Please email or call us today with any questions or concerns.